Retatrutide is a novel 39-amino acid triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program) — the most advanced metabolic research peptide available today.
Molecular Weight: ~4,480 g/mol
Purity: ≥99% HPLC tested
Format: Lyophilized powder
Storage: -20°C
Research areas: Metabolic research · Liver fat reduction · Glycemic control · Thermogenesis · Appetite regulation
🍁 Canada-wide shipping · Free shipping over $300 CAD · Same-day dispatch before 2pm EST
For research purposes only. Not approved by Health Canada.




Reviews
There are no reviews yet.